Divi's Laboratories Ltd.Strong Growth Amid Supply Headwinds

Divi's Laboratories delivered robust FY26 performance with total income rising fourteen percent year-on-year to ₹11,067 crores, while profit after tax grew even faster at seventeen percent to ₹2,568 crores, demonstrating operational efficiency despite challenging conditions.

The company navigated geopolitical supply chain disruptions in West Asia without production stoppages by strengthening its supplier base and domestic procurement network, though freight cost inflation and generic pricing pressure compressed margins from historical levels of thirty-seven to thirty-eight percent down to thirty-two percent. Management maintained cautious optimism, targeting double-digit revenue growth for FY27 while expecting margins to stabilize around current levels.

Strategic progress includes Unit 3 capacity optimization freeing GMP space, successful validation of multiple peptide fragments with 3,000-liter SPPS capacity operational, and commercial-scale iodine-based contrast media production for innovator customers. The company capitalized ₹1,544 crores during the year with ₹2,113 crores in capital work in progress, positioning for revenue conversion over FY27-FY29 as three dedicated custom synthesis projects advance through customer regulatory approvals.